|Place of Origin:||China|
|Minimum Order Quantity:||300, 000 tablets|
|Payment Terms:||L/C, T/T|
|Supply Ability:||one million pills per day|
|Product:||Rosiglitazone Tartrate Dispersible Tablets||Specification:||4mg|
|Standard:||In - House||Packing:||6’s/blister|
Rosiglitazone Tartrate Dispersible Tablets 4mg Oral Medications
Product : Rosiglitazone Tartrate Dispersible Tablets
Specification : 4mg
Standard : In - house
Packing : 6’s/blister
Rosiglitazone Tartrate is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. Rosiglitazone Tartrate improves glycemic control while reducing circulating insulin levels.
Rosiglitazone Tartrate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.
Each pentagonal film-coated tablet contains rosiglitazone Tartrate equivalent to rosiglitazone 4 mg for oral administration.
Indications and Usage :
1 Monotherapy and Combination Therapy
Rosiglitazone Tartrate Dispersible Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2 Important Limitations of Use
Due to its mechanism of action, Rosiglitazone Tartrate Dispersible Tablets is active only in the presence of endogenous insulin. Therefore, Rosiglitazone Tartrate Dispersible Tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
The coadministration of Rosiglitazone Tartrate Dispersible Tablets and insulin is not recommended.
The use of Rosiglitazone Tartrate Dispersible Tablets with nitrates is not recommended.
When rosiglitazone is used as monotherapy, it is associated with increases in total cholesterol, LDL, and HDL. It is also associated with decreases in free fatty acids. Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time.
Mechanism of action
Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.